Journal profile · Biochemistry, Genetics and Molecular Biology-Molecular Medicine
Biomarker Research
ISSN 2050-7771 · BioMed Central · ENGLAND · Founded 2013
Biomarker Research: CAS Zone 2 · Medicine (2025 upgraded edition); impact factor 14.54; fully open access; APC about USD 4,090; median 92 days to acceptance (99 articles, last 24 months); 166 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Biomarker Research is published by BioMed Central and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research and Acute Myeloid Leukemia Research, together about 22.2% of its articles. Its main subfields are Cancer Research. (generated from OpenAlex topic counts and CAS ranking data)
Biomarker Research is an open access, peer-reviewed journal that encompasses all aspects of biomarker investigation. Biomarker Research aims to publish original discoveries, novel concepts, commentaries and reviews related to biomarker investigation from all biomedical disciplines. The study of biomarkers has evolved rapidly in the advance of personalized medicine and individual health. The identification and validation of biomarkers in drug discovery/development and in disease diagnosis, treatment, prognosis, and prevention play an essential role in the genome era. With a quick turnaround time from submission to publication and online feedback from readers, Biomarker Research strives to provide fast dissemination of novel findings and new knowledge.
From the journal's Aims & Scope
Research area (LetPub): Biochemistry, Genetics and Molecular Biology-Molecular Medicine
Editor-in-chief Chung-Tsen HsuehPublisher website
Editorial board by country: 11 in mainland China (about 24%); most named United States 14, Mainland China 11, Taiwan, China 3, Germany 3, Spain 3 (45 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Cancer Immunotherapy and BiomarkersMedicine8.5%
- CAR-T cell therapy researchMedicine7.5%
- Acute Myeloid Leukemia ResearchMedicine6.2%
- Cancer-related molecular mechanisms researchBiochemistry, Genetics and Molecular Biology5.5%
- RNA modifications and cancerBiochemistry, Genetics and Molecular Biology5.3%
- Immune cells in cancerImmunology and Microbiology5.2%
- MicroRNA in disease regulationBiochemistry, Genetics and Molecular Biology4.8%
- Lymphoma Diagnosis and TreatmentMedicine4.3%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Medicine, Research & Experimental | Zone 2 |
| Minor | Oncology | Zone 2 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Oncology | Zone 2 |
| Minor | Medicine, Research & Experimental | Zone 2 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Medicine, Research & Experimental | Zone 2 |
| Minor | Oncology | Zone 2 |
Top journal: noReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
EmbaseCASCurrent ContentsPublisher website
Other: Google Scholar, ProQuest, Dimensions, CNKI, Baidu, Naver, OCLC, Portico, CLOCKSS
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 14.54LetPub ·
- Impact factor (publisher) 2025
- 14.6Publisher website ·
- 5-year impact factor (publisher) 2025
- 13.9Publisher website ·
- CiteScore 2026-06
- 18.5LetPub ·
- SJR 2026-06
- 3.3LetPub ·
- SNIP 2026-06
- 2.15LetPub ·
- h-index
- 92OpenAlex ·
- i10-index
- 644OpenAlex ·
- 2-year mean citedness
- 15.1OpenAlex ·
- Self-citation rate
- 0.7%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 128LetPub ·
- Downloads per year (publisher) 2025
- 2,100,000Publisher website ·
Articles by year OpenAlex count · 1,029 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 123 | 123 | 176 |
| 2025 | 166 | 166 | 2,379 |
| 2024 | 166 | 166 | 4,316 |
| 2023 | 106 | 106 | 3,433 |
| 2022 | 91 | 91 | 4,393 |
| 2021 | 92 | 92 | 5,117 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
92 daysMedian, submission to acceptance · P25–P75 60 days – 126 days
- Acceptance to online
- median 15 days (99 articles)
- Submission to online
- median 115 days
- Sample
- 99 articles with submission and acceptance dates (346 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 10 weeksLetPub ·
- Submission to first decision
- 11 daysPublisher website ·
- Submission to publication (journal-reported)
- about 10 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | EUR 3,190 / USD 4,090 / GBP 2,890 | Yes | CC BY, CC BY-NC-ND | |
| OpenAlex | USD 3,890 / EUR 3,090 / GBP 2,790 | — | — | |
| LetPub | GBP 2,690 / USD 3,690 / EUR 2,990 | Yes | — | |
| Publisher website | GBP 2,890 / USD 4,090 / EUR 3,190 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Open calls for papers1, by deadline
Publisher websiteWhat to prepare1 items from the author guidelines
- Suggested reviewers
- Optional
Article types accepted6
- case reportFormatting guidelines for specific article types can be found below. Research Review Correspondence Methodology Research highlight Case reportLength not stated
- correspondenceFormatting guidelines for specific article types can be found below. Research Review Correspondence Methodology Research highlight Case reportLength not stated
- methodologyFormatting guidelines for specific article types can be found below. Research Review Correspondence Methodology Research highlight Case reportLength not stated
- researchFormatting guidelines for specific article types can be found below. Research Review Correspondence Methodology Research highlight Case reportLength not stated
- research highlightFormatting guidelines for specific article types can be found below. Research Review Correspondence Methodology Research highlight Case reportLength not stated
- reviewFormatting guidelines for specific article types can be found below. Research Review Correspondence Methodology Research highlight Case reportLength not stated
Policy excerpts from the journal's websiteData availability, License & copyright, Open access, Peer review
- Data availability Formatting the 'Availability of data and materials' section of your manuscript
The following format for the 'Availability of data and materials section of your manuscript should be used:
Source ↗Publisher website ·- License & copyright Licensing and copyright
Creative Commons licences Open access articles in Springer Nature journals are published under Creative Commons licences. These provide an industry-standard framework to support easy re-use of open access material. Under Creative Commons licences, authors retain copyright of their articles. Biomarker Research articles are published open access under a CC BY-NC-ND (Creative Commons Attribution Non-…
Source ↗Publisher website ·- Open access Benefits of open access
Publishing open access (OA) offers a number of benefits, including greater reach and readership for your work: Cited more 1.6x more citations of OA articles than non-OA articles across all subjects Downloaded more 4x more downloads of OA articles than non-OA articles Greater impact 2.5x more Altmetric attention. OA articles attracted 1.9x more news mentions and 1.2x more policy mentions Open acces…
Source ↗Publisher website ·- Peer review Peer review policy
Peer review is the process used to evaluate the quality of a manuscript before publication. Independent researchers in the relevant field assess submitted manuscripts to check their validity and robustness. Their feedback guides editors in making publication decisions. Typically, two or more experts evaluate each manuscript based on three main criteria: scientific robustness: is the research metho…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- BioMed Central
- Country or region
- ENGLAND
- Language
- English
- Founded
- 2013
- ISSN
- 2050-7771
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗LetPub
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Biomarker Research
What CAS zone is Biomarker Research in?
In the 2025 upgraded edition of the CAS Journal Ranking, Biomarker Research is in Zone 2 of Medicine, and in Zone 2 of the minor category Medicine, Research & Experimental / Oncology. In the 2026 Xinrui edition it is in Zone 1 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Biomarker Research?
The latest impact factor listed by LetPub is 14.54; CiteScore 18.5, h-index 92.
How long does peer review take at Biomarker Research?
Based on the dates recorded on 99 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 92 days (interquartile range 60–126 days); authors report an average review time of about 10 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Biomarker Research based?
Of the 45 board members whose country the journal's board page names, 11 (about 24%) are in mainland China; the countries named most often are United States (14), Mainland China (11) and Taiwan, China (3). Counted from the institutions listed on the board page; for reference only.
Which databases index Biomarker Research?
According to LetPub and DOAJ records, Biomarker Research is indexed in SCIE, Scopus and DOAJ. The journal's website also lists Embase, CAS and Current Contents; that list has not been checked against each database.
Is Biomarker Research open access, and what is the APC?
Biomarker Research is a fully open-access journal. APC about USD 4,090.
Sources and updates
The facts on this page come from LetPub, OpenAlex, DOAJ, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .